Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Newly Diagnosed Glioblastoma × efineptakin alfa × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioma 3 Glioblastoma 3 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 Newly Diagnosed Glioblastoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms 1 Melanoma 1 Lymphopenia 1 Gliosarcoma 1

Interventions

efineptakin alfa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065087 2022-03-17

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Genexine, Inc.

Phase 1/2 Withdrawn

Newly Diagnosed Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡